NXL Nexalin Technology (NXL) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001527352
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter
What the filings say about NXL
Activist stakes (13D), 180 days
1 filing
Largest: 5.6% of the class
Nexalin Technology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Nexalin Technology, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 14, 2024.
- The trade is 20.0% of the 30,000 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought about $13.2K of NXL on Mar 12, 2025; 7 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Jan 28, 2025.
- -29.1% median (+4.9% mean) 90-day return after 10 previous buys.
- The trade is 0.6% of the 155,793 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Owens David bought about $3.1K of NXL on Feb 4, 2025; 7 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Jan 28, 2025.
- -29.1% median (+4.9% mean) 90-day return after 10 previous buys.
- The trade is 0.6% of the 154,793 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Owens David bought about $3.0K of NXL on Feb 4, 2025; 7 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Jan 23, 2025.
- -29.1% median (+8.6% mean) 90-day return after 9 previous buys.
- The trade is 1.0% of the 153,793 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Owens David bought about $4.1K of NXL on Jan 28, 2025; 7 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Jan 13, 2025.
- -17.4% median (+13.8% mean) 90-day return after 8 previous buys.
- The trade is 0.7% of the 152,293 shares held after it.
- No other insider bought within 30 days.
- 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Owens David bought about $2.7K of NXL on Jan 23, 2025; 7 funds added in the latest 13F quarter.22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 92% of Medical Devices
Revenue
+78.8% year over year
more than 90% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 88% of Medical Devices
The situation: each line is one rule over one dataset
Greenlight Ventures, LLC disclosed a 5%+ stake (5.6%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NXL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+15.5%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NXL: institutional holders (13F)
13F holdings, latest reported quarter
240,210 sh
$79.3K
139,583 sh
$46.1K
126,536 sh
$41.8K
75,398 sh
$24.9K
65,497 sh
$21.6K
Congress trades in NXL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Greenlight Ventures, LLC
Activist 13D · 2026-09-03
5.6%
NXL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NXL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$112.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$41.8K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$10.1K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$2.3K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$10.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NXL financials
Revenue growth
+78.8%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$217.2K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NXL
| FY Dec 2025 | $301.6K |
| FY Dec 2024 | $168.7K |
| FY Dec 2023 | $110.7K |
| FY Dec 2022 | $1.3M |
| FY Dec 2021 | n/a |
| Jun 2026 | $12.2K |
| Mar 2026 | $14.9K |
| Dec 2025 | $171.9K |
| Sep 2025 | $18.1K |
| Jun 2025 | $70.6K |
| Mar 2025 | $41.0K |
| Dec 2024 | $27.2K |
| Sep 2024 | $36.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -128.5% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-240.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NXL
| FY Dec 2025 | -221.5% |
| FY Dec 2024 | -221.1% |
| FY Dec 2023 | -107.0% |
| FY Dec 2022 | -89.4% |
| FY Dec 2021 | n/a |
| Jun 2026 | -240.3% |
| Mar 2026 | -319.7% |
| Dec 2025 | -221.5% |
| Sep 2025 | -178.5% |
| Jun 2025 | -242.0% |
| Mar 2025 | -367.7% |
| Dec 2024 | -221.1% |
| Sep 2024 | -135.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-187.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NXL
| FY Dec 2025 | -185.6% |
| FY Dec 2024 | -193.7% |
| FY Dec 2023 | -84.0% |
| FY Dec 2022 | -41.5% |
| FY Dec 2021 | -806.4% |
| Jun 2026 | -187.9% |
| Mar 2026 | -252.6% |
| Dec 2025 | -185.6% |
| Sep 2025 | -167.2% |
| Jun 2025 | -217.8% |
| Mar 2025 | -298.4% |
| Dec 2024 | -193.7% |
| Sep 2024 | -114.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-243.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NXL
| FY Dec 2025 | -226.0% |
| FY Dec 2024 | -225.3% |
| FY Dec 2023 | -131.1% |
| FY Dec 2022 | -94.7% |
| FY Dec 2021 | n/a |
| Jun 2026 | -243.9% |
| Mar 2026 | -326.2% |
| Dec 2025 | -226.0% |
| Sep 2025 | -182.0% |
| Jun 2025 | -246.5% |
| Mar 2025 | -373.7% |
| Dec 2024 | -225.3% |
| Sep 2024 | -158.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NXL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $301.6K | $168.7K | $110.7K | $1.3M |
| Gross profit | $240.3K | $132.1K | $85.1K | $958.1K |
| Operating income | -$8.4M | -$7.8M | -$5.7M | -$1.8M |
| Net income | -$8.2M | -$7.6M | -$4.6M | -$1.7M |
| EPS (diluted) | -0.50 | -0.83 | -0.63 | -0.30 |
| Operating cash flow | -$5.0M | -$3.9M | -$3.8M | -$2.2M |
| Cash | $654.8K | $574.5K | $580.2K | $162.7K |
SEC XBRL, fiscal years, as known on 2026-10-28
NXL Stock Sonar score 4/7 axes
Find similar shapesCompareNXL ranks highest on growth (90th percentile) and risk and compliance (72nd), and lowest on profitability (9th), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NXL filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 5.6% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
